While we acknowledge that ndufs4 mutations have not been directly implicated in LHON, a mutation-independent therapeutic strategy that is protective of RGCs in the setting of ndufs4 inactivation would seem to have a high likelihood of efficacy in treating the much less severe complex I dysfunction seen in LHON patients. This evidence concerns the gene NDUFS4 and Leber hereditary optic neuropathy.